sTLR4/MD-2 complex inhibits colorectal cancer in vitro and in vivo by targeting LPS
Metrics: PDF 2117 views | HTML 2219 views | ?
Yan Zou1,*, Fengxian Qin1,*, Jifei Chen1,*, Jie Meng1, Liuhua Wei1, Chunlin Wu1, Qiaoyun Zhang1, Dong Wei1, Xiang Chen1, Hao Wu1, Xiaoli Chen1, Shengming Dai1
1Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, P.R. China
*These authors have contributed equally to this work
Shengming Dai, email: [email protected]
Keywords: sTLR4/MD-2 complex, CRC, LPS, pro-inflammatory cytokine, migration cytokine
Received: February 23, 2016 Accepted: June 30, 2016 Published: July 08, 2016
Colorectal cancer (CRC) is aggressive and associated with TLR4-MD-2 signaling. Toll-like receptor 4 (TLR4) and myeloid differentiation protein 2 (MD-2) were highly expressed in human CRC. The soluble form of extracellular TLR4 domain (sTLR4) and MD-2 may have important roles in binding lipopolysaccharide (LPS). In this study, sTLR4 and MD-2 protein and prepared sTLR4/MD-2 complex were synthesized successfully to restrain LPS-TLR4/MD-2 activation by competing with cellular membrane TLR4 for binding LPS. The sTLR4/MD-2 complex can significantly attenuate LPS induced pro-inflammatory and migration cytokine production in vitro and in vivo, and inhibit the effect of LPS on the cell cycle, migration and invasion of human CRC cells in vitro. Administration of sTLR4/MD-2 complex protected mice from tumor both in xenograft and implantation metastasis model. The sTLR4/MD-2 complex treated mice had smaller tumor, less body weight loss and lower expression of inflammatory cytokines. Here, the azoxymethane/dextran sulfate sodium salt (AOM/DSS) murine model was used as an experimental platform to simulate the physiological and pathological processes of cancers associated with chronic intestinal inflammation. AOM/DSS-induced tumors were inhibited in mice treated by sTLR4/MD-2 complex. It is demonstrated in our study that sTLR4/MD-2 complex could inhibit CRC by competing with binding LPS, raising the complex’s possibility of a new prevention agent against CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.